Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116054 | 0.85 | BCHE (0.47) | ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL4161374 | 0.81 | CHRM4 (0.44) | ALDH1A1L3MBTL1 | |
| SCHEMBL1697177 | 0.81 | CHRM4 (0.44) | ALDH1A1L3MBTL1 | |
| SCHEMBL5385059 | 0.81 | CHRM4 (0.43) | ALDH1A1L3MBTL1 | |
| SCHEMBL20476348 | 0.77 | KDM4E (0.41) | ALDH1A1KDM4E | |
| SCHEMBL5115681 | 0.76 | TACR3 (0.52) | ALDH1A1POLBTACR3LMNARAB9A | |
| SCHEMBL4190993 | 0.75 | GRIN2B (0.39) | ALDH1A1 | |
| SCHEMBL1999955 | 0.75 | SLC6A2 (0.40) | ALDH1A1KDM4E | |
| SCHEMBL4193805 | 0.74 | GRIN2B (0.38) | ALDH1A1KDM4E | |
| SCHEMBL4180019 | 0.73 | POLB (0.33) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465751-B2 | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-16 | — | — | US | disclosed |
| US-20060194862-A1 | 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | US | disclosed |
| EP-1583741-A1 | 1-SUBSTITUTED-3-PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories, Limited (IN) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004056767-A1 | 1-SUBSTITUTED-3-PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194862-A1 | 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | CHRM3, CHRM1, CHRM5 | ALDH1A1 821/4885POLB 2285/4885TACR3 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.